معرفی
Karin de Visser is a Group Leader at the Netherlands Cancer Institute's Division of Immunology, with a research focus on tumor immunology and inflammation's role in cancer progression. She leads a multidisciplinary team exploring breast cancer metastasis and immunotherapy, utilizing pre-clinical mouse models and patient immune profiling.
- PhD from Free University Amsterdam (2002)
- Postdoctoral training at UCSF (2003-2005)
- Research Staff Associate at NKI (2008-2012)
- Junior Group Leader (2012-2015)
Her research investigates how immune cells interact with tumor cells to influence metastasis and therapy response. Key areas include:
- Systemic inflammatory mechanisms in cancer progression
- P53 mutation-driven immune evasion
- Macrophage-targeted immunochemotherapy
- Immune checkpoint blockade synergies
Recent publications highlight her work on:
- 2023 - IL-5 signaling in CD4+ T cells and eosinophils improving immunotherapy
- 2019 - Macrophage targeting to enhance chemotherapy via interferon pathways
- 2019 - P53 loss driving WNT-mediated inflammation for metastasis
Honors include:
- 2016 EMBO Young Investigator
- 2015 Metastasis Research Prize
- 2014 ERC Consolidator Grant
- 2009 NWO-VIDI award
Her team includes current PhD students and postdoctoral fellows such as Daniil Anastasopoulos, Noor Bakker, Seth Coffelt, and Kevin Kos. Research facilities include NKI's tumor biology platforms and mouse models of breast cancer.
